In accordance with XenoPort’s collaboration agreements with GlaxoSmithKline and Astellas Pharma the FDA’s acceptance of the new drug application (NDA) triggers milestone payments to XenoPort of $23 million in the aggregate.
Solzira is a new chemical entity that is designed to improve upon the pharmacokinetics of Solzira (gabapentin) by taking advantage of high-capacity transport mechanisms in the gastrointestinal tract to improve absorption.